Finerenone in heart failure with left ventricular ejection fraction ≥40%: a correspondence
{{output}}
Finerenone, the first nonsteroidal mineralocorticoid receptor antagonist approved by the U.S. Food and Drug Administration for treating heart failure (HF) with mildly reduced ejection fraction and HF with preserved ejection fraction reduces morbidity and morta... ...
